Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 1
2013 2
2015 6
2016 10
2017 7
2018 6
2019 9
2020 11
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, Xia M, Chang X, Lu Y, Li Y, Xia P, Li X, Gao X. Zhu X, et al. Free Radic Biol Med. 2019 Sep;141:192-204. doi: 10.1016/j.freeradbiomed.2019.06.019. Epub 2019 Jun 18. Free Radic Biol Med. 2019. PMID: 31226399
BACKGROUND: Berberine (BBR), a natural compound extracted from Chinese herb, has been shown to effectively attenuate nonalcoholic fatty liver disease (NAFLD) in clinic. ...METHODS: The expression of SCD1 was measured in the liver of NA
BACKGROUND: Berberine (BBR), a natural compound extracted from Chinese herb, has been shown to effectively attenuate nonalcoholic …
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
Cicero AFG, Colletti A, Bellentani S. Cicero AFG, et al. Nutrients. 2018 Aug 23;10(9):1153. doi: 10.3390/nu10091153. Nutrients. 2018. PMID: 30142943 Free PMC article.
Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese
Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltrat
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, Zeng MS, Tu YF, Feng R, Jia WP, Liu J, Deng W, Jiang JD, Gao X. Yan HM, et al. PLoS One. 2015 Aug 7;10(8):e0134172. doi: 10.1371/journal.pone.0134172. eCollection 2015. PLoS One. 2015. PMID: 26252777 Free PMC article. Clinical Trial.
OBJECTIVES: A randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berberine (BBR) on NAFLD. METHODS: A randomized, parallel controlled, open-label clinical trial was conducted in three medical centers …
OBJECTIVES: A randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berbe
Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.
Wang Y, Zhou X, Zhao D, Wang X, Gurley EC, Liu R, Li X, Hylemon PB, Chen W, Zhou H. Wang Y, et al. PLoS One. 2020 May 1;15(5):e0232630. doi: 10.1371/journal.pone.0232630. eCollection 2020. PLoS One. 2020. PMID: 32357187 Free PMC article.
Inflammation plays an essential role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Berberine (BBR), an isoquinoline alkaloid isolated from Chinese medicinal herbs, has been widely used to treat various diseases, …
Inflammation plays an essential role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.
Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, Yan H, Zhang Y, Gu Y, Shi H, Li J, Gao X, Li J. Wu L, et al. Cell Death Dis. 2019 Jun 13;10(6):468. doi: 10.1038/s41419-019-1706-y. Cell Death Dis. 2019. PMID: 31197160 Free PMC article.
Brown adipose tissue (BAT) dissipates metabolic energy and mediates non-shivering thermogenesis, thereby boosting energy expenditure. ...Here, we reported that 1-month BBR intervention increased BAT mass and activity, reduced body weight, and improved insulin sensitivity i …
Brown adipose tissue (BAT) dissipates metabolic energy and mediates non-shivering thermogenesis, thereby boosting energy expenditure. …
Herbal drug discovery for the treatment of nonalcoholic fatty liver disease.
Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Yan T, et al. Acta Pharm Sin B. 2020 Jan;10(1):3-18. doi: 10.1016/j.apsb.2019.11.017. Epub 2019 Dec 10. Acta Pharm Sin B. 2020. PMID: 31993304 Free PMC article. Review.
Few medications are available for meeting the increasing disease burden of nonalcoholic fatty liver disease (NAFLD) and its progressive stage, nonalcoholic steatohepatitis (NASH). ...Against this proposed model, the effects and mechanisms of the …
Few medications are available for meeting the increasing disease burden of nonalcoholic fatty liver disease ( …
Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice.
Luo Y, Tian G, Zhuang Z, Chen J, You N, Zhuo L, Liang B, Song Y, Zang S, Liu J, Yang J, Ge W, Shi J. Luo Y, et al. Am J Transl Res. 2019 May 15;11(5):2668-2682. eCollection 2019. Am J Transl Res. 2019. PMID: 31217846 Free PMC article.
Hepatocellular carcinoma (HCC) is one of the most malignant and poor prognosis tumors, which was increasingly caused by nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) in western countries. ...The effect of berberine i …
Hepatocellular carcinoma (HCC) is one of the most malignant and poor prognosis tumors, which was increasingly caused by nonalcoholic fatt
Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function.
Rafiei H, Omidian K, Bandy B. Rafiei H, et al. Nutrients. 2019 Mar 3;11(3):541. doi: 10.3390/nu11030541. Nutrients. 2019. PMID: 30832407 Free PMC article.
In this study, we aimed to determine the relative effectiveness of common dietary polyphenols or the isoquinoline alkaloid berberine in protecting against molecular mechanisms underlying non-alcoholic fatty liver disease (NAFLD) in …
In this study, we aimed to determine the relative effectiveness of common dietary polyphenols or the isoquinoline alkaloid berberine
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.
Chang X, Wang Z, Zhang J, Yan H, Bian H, Xia M, Lin H, Jiang J, Gao X. Chang X, et al. J Transl Med. 2016 Sep 15;14:266. doi: 10.1186/s12967-016-0982-x. J Transl Med. 2016. PMID: 27629750 Free PMC article. Clinical Trial.
We used a lipidomic approach to characterize the state of lipid metabolism as reflected in the circulation of subjects with nonalcoholic fatty liver disease (NAFLD) before and after berberine treatment. ...CONCLUSIONS: Berberine altered c …
We used a lipidomic approach to characterize the state of lipid metabolism as reflected in the circulation of subjects with nonalcoholic …
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
Zhu X, Bian H, Gao X. Zhu X, et al. Molecules. 2016 Oct 14;21(10):1336. doi: 10.3390/molecules21101336. Molecules. 2016. PMID: 27754444 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD) is a globally observed metabolic disease with high prevalence both in adults and children. ...The immunologic mechanism of BBR in the treatment of NAFLD, development of berberine derivative, …
Nonalcoholic fatty liver disease (NAFLD) is a globally observed metabolic disease with high prevalence bo …
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page